FDA Approves Cosentyx for Adolescent Hidradenitis Suppurativa | Healio

The Food and Drug Administration has approved Novartis’ Cosentyx (secukinumab) for use in adolescents aged 12 years and older living with moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin condition. This marks the first time an interleukin-17A (IL-17A) inhibitor has been authorized for this pediatric population, addressing a significant gap in treatment options for young people often diagnosed with HS during their teenage years.

Understanding Hidradenitis Suppurativa

Hidradenitis suppurativa is a chronic, autoinflammatory disease characterized by painful, recurring lesions—often in areas where skin rubs together, such as the armpits, groin, and under the breasts. These lesions can lead to scarring and significantly impact quality of life. Estimates suggest that between 1% and 4% of the population is affected, with more than half experiencing symptom onset during adolescence. As previously reported by Healio, Cosentyx received FDA approval for adults with HS in 2023.

Evidence Supporting the Pediatric Approval

The approval for adolescents is not based on modern clinical trials specifically conducted in that age group. Instead, the FDA based its decision on data extrapolated from well-controlled studies in adults, pharmacokinetic modeling, and existing data from pediatric trials for other approved indications of secukinumab, such as psoriasis. Novartis explained that dosing analysis indicated weight-based dosing in pediatric patients would achieve similar drug exposure levels as seen in adult HS patients.

Alexa B. Kimball, MD, MPH, lead investigator of the SUNSHINE and SUNRISE clinical trials in adult HS patients, and president and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, emphasized the importance of this approval. “Hidradenitis suppurativa often begins in adolescence and can cause irreversible scarring and disabilities,” she stated in a Novartis press release. “The approval of Cosentyx represents an crucial advancement for younger HS patients who have had limited treatment options.”

How Cosentyx Works: Targeting IL-17A

Cosentyx is a monoclonal antibody that selectively blocks the activity of IL-17A, a protein involved in inflammation. In HS, IL-17A plays a key role in the inflammatory processes that drive the development of lesions. By inhibiting IL-17A, Cosentyx aims to reduce inflammation and alleviate symptoms. It’s important to note that although Cosentyx can aid manage symptoms, This proves not a cure for HS.

What This Means for Patients and Families

Prior to this approval, treatment options for pediatric HS were often limited to topical therapies, antibiotics, and, in some cases, systemic medications with varying degrees of effectiveness and potential side effects. The availability of Cosentyx offers a new, targeted treatment option for adolescents with moderate to severe HS, potentially improving their quality of life and reducing the long-term impact of the disease. However, as with any medication, it’s crucial to discuss the potential benefits and risks with a qualified healthcare professional.

Expanding Access and Real-World Experience

Victor Bultó, president of Novartis US, highlighted the company’s commitment to addressing unmet needs in HS. “With more than a decade of real-world experience across multiple autoimmune diseases, Cosentyx is a well-established treatment option that many physicians trust,” Bultó said in the press release. “Yet for young people living with moderate to severe hidradenitis suppurativa, treatment options have remained limited for far too long. Expanding Cosentyx to this population addresses a critical gap in care and underscores our focus on advancing solutions where One can make the greatest impact on outcomes.”

Looking Ahead: Ongoing Research and Monitoring

The FDA approval is a significant step forward, but ongoing research and monitoring will be crucial. Post-market surveillance will help to gather real-world data on the safety and effectiveness of Cosentyx in pediatric patients. Further studies may also be conducted to optimize dosing regimens and identify biomarkers that can predict treatment response. The FDA will continue to monitor reports of adverse events and update guidance as needed. Clinicians are encouraged to report any unexpected or serious side effects to the FDA’s MedWatch program. More information about MedWatch can be found on the FDA website.

For families and individuals affected by HS, staying informed about the latest research and treatment options is essential. Resources such as the Hidradenitis Suppurativa Trust (https://www.hs-trust.org/) offer valuable information and support.